September 25th 2023
C. Ola Landgren, MD, PhD, discussed the ASCENT trial and his predictions for future developments in the myeloma space.
During a Targeted Oncology™ Case-Based Roundtable™ event, Naveen Pemmaraju, MD, explained the research he and others conducted leading to the development of tagraxofusp-erzs to treat patients with blastic plasmacytoid
dendritic cell neoplasm.
September 9th 2023
Evolving research has now shown that immunotherapies can be combined with one another and used to specifically target the cancer cells.
In an interview with Targeted Oncology, Amer Zeidan, MBBS, discussed the IMerge study and next steps for imetelstat for patients with lower-risk MDS.
September 8th 2023
In the third article of this series, Eytan M. Stein, MD, discusses the treatment landscape for patients with lower-risk MDS and reviews follow-up data from the IMerge clinical trial.
Current Methods for Prognostication and Management of Lower-Risk MDS
Uwe Platzbecker, MD, discussed findings from recent phase 3 trials and their clinical implications for daily care in patients with lower-risk myelodysplastic neoplasms.
Exploring Survival Disparities in Hematologic Malignancies
An analysis examined survival outcomes in several subgroups of patients with hematologic cancers compared with the overall population.
Luspatercept Lessens RBC Transfusion Burden in MDS
Results from the COMMANDS trial led the FDA to approve luspatercept for the treatment of anemia without prior erythropoiesis-stimulating agent use in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell transfusions.
Current and Emergent Therapies for Systemic Mastocytosis
The field of mastocytosis is witnessing a paradigm shift with precision medicine in the form of mutant KIT inhibitors.
Is It Time to Bring Back the French American British Classification System?
Learning more about monocytic resistance to venetoclax is a new direction toward improving outcomes for patients with acute myeloid leukemia.
Roundtable Roundup: Graft-vs-Host Disease
In separate live virtual events, Pashna N. Munshi, MD; Navneet Majhail, MD, MS; and participants at the respective discussions considered treatment options for a patient with chronic graft-vs-host disease (GVHD) after multiple previous treatment attempts.
Considering Outpatient Use of Tagraxofusp for BPDCN in the Community Setting
During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed with other oncologists concerning the practical considerations for outpatient use of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasm.
FDA Approves Luspatercept-aamt for Upfront Treatment of Anemia in Lower-Risk MDS
The FDA has added to the existing approval of luspatercept-aamt for the treatment of patients with anemia and lower-risk myelodysplatic syndrome.
Clinical Experience with Ruxolitinib for cGVHD
Experienced hematologist-oncologists offer their clinical experiences with ruxolitinib.
FDA to Review Imetelstat NDA for Transfusion-Dependent Anemia in Lower-Risk MDS
On the heels of promising findings from the phase 3 IMerge study, the FDA has accepted the new drug application of imetelstat for transfusion-dependent anemia in patients with lower-risk MDS.
Emerging Therapies Are Explored in Low- and High-Risk MDS
For patients who are ineligible for erythropoiesis-stimulating agents, luspatercept-aamt offers a new approach.
Trials Seek to Assess New Treatments for Lower-Risk MDS
Guillermo Garcia-Manero, MD, discussed 2 studies evaluating therapies for patients with lower-risk myelodysplastic syndrome.
The REACH3 Clinical Trial of Ruxolitinib in Chronic GVHD
Yi-Bin Chen reviews data from the REACH3 trial of ruxolitinib in patients with chronic steroid-refractory graft versus host disease.
Identifying When Additional Treatment Is Needed for cGVHD
During a Targeted Oncology™ Case-Based Roundtable™ event, Carrie L. Kitko, MD, discussed whether to biopsy a patient with chronic GVHD and what treatment to use following steroids.
Ivosidenib Granted Priority Review by FDA for IDH1+ R/R Myelodysplastic Syndromes
The FDA plans to conduct a speedy review of the supplemental new drug application for ivosidenib tablets as treatment of IDH1-positive, relapsed or refractory myelodysplastic syndrome.
Data Updates From the IMerge Trial
In the second article of this series, Abdulraheem Yacoub, MD, discusses recent updates from the IMerge clinical trial, which is studying imetelstat in patients with low-risk MDS.
Ibrutinib as Second-Line Therapy for Steroid-Refractory Chronic GVHD
Catherine Lee reviews data on use of ibrutinib for steroid-refractory chronic graft versus host disease.
Therapy Options for Steroid-Refractory Chronic GVHD
Experts in the treatment of graft versus host disease evaluate second-line agents for patients with steroid-refractory disease.
Zanubrutinib Shows Lasting Responses in Waldenström Macroglobulinemia
Two-year follow up data of the phase 3 ASPEN study shows support for the long term benefits of zanubrutinib in patients with previously treated Waldenström macroglobulinemia.
FDA Denies Approval of Remestemcel-L for Pediatric SR-aGVHD
Despite a favorable vote by the Oncologic Drugs Advisory committee, the FDA has opted not to approve remestemcel-L for the treatment of pediatric steroid-refractory acute graft-vs-host disease.
Study of SYNCAR-001 and STK-009 Begins in CD19+ Hematologic Malignancies
The phase 1 study is evaluating the combination of a CD19-targeting chimeric antigen receptor and an orthogonal IL-2 in patients with CD19-positive hematologic malignancies.
Crossover Patients With GVHD Respond to Ruxolitinib in REACH3 Trial
The REACH3 study showed ruxolitinib to elicit a high efficacy rate and have a manageable safety profile in patients with chronic graft-versus-host disease.
Steroid-Refractory Chronic GVHD Background
The categories of steroid refractory gvhd are discussed: intolerant, unresponsive, and dependent.
Treatment Goals for a Patient With Chronic GVHD
The group discusses treatment goals and patient education for chronic GVHD.
IMerge Trial: Key Efficacy Outcomes
Following the 2023 ASCO Annual Meeting, Abdulraheem Yacoub, MD, reviews key data updates from the IMerge trial investigating imetelstat in patients with lower-risk MDS.
Various Doses of Axatilimab Generate Positive Responses in cGVHD
Positive topline results from the AGAVE-201 trial have led the companies to submit a biologics license application to the FDA by the end of 2023.
Physicians Review Diagnosis and Management of BPDCN
During a Targeted Oncology™ Case-Based Roundtable™ event, Daniel Pollyea, MD, MS, and participants discussed the diagnosis and treatment of a patient with blastic plasmacytoid dendritic cell neoplasm.
Patient Case: A 48-Year-Old Man with Chronic GVHD
Dr Chen and Dr Cutler review a clinical case and discuss GVHD assessment for the patient.
The Chronic GVHD Treatment Paradigm
Dr Lee shares an overview of therapy and supportive care options for chronic GVHD according to the severity of a symptom.
Ponce Discusses Use of Steroids and Next-Line Treatment for Chronic GVHD
During a Targeted Oncology™ Case-Based Roundtable™ event, Doris M. Ponce, MD, and participants discussed treatment goals and management of graft-vs-host disease.
2 Clarke Drive Cranbury, NJ 08512